A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (clinicaltrials.gov) - Sep 22, 2026 - P1/2 | N=41 | Active, not recruiting | Sponsor: Ravi Amaravadi, MD | Trial primary completion date: Nov 2026 ➔ Jul 2026
Trial primary completion date • Melanoma • Oncology • Solid Tumor • PD-L1
|